CRISPR Therapeutics Announces Transition of Chief Financial Officer

CRISPR治疗公司宣布首席财务官换届

2021-10-14 22:30:07 BioSpace

本文共1459个字,阅读需4分钟

ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 14, 2021 -- CRISPR Therapeutics , a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Brendan Smith as Chief Financial Officer, effective today. Mr. Smith brings more than 20 years of financial, operational and strategic leadership experience, including as CFO of Translate Bio. He succeeds Michael Tomsicek, who is retiring after four years of service to the Company. It is expected that Mr. Tomsicek will remain with the Company in an advisory role through the end of 2021 to help ensure a smooth transition. “I'm excited to welcome Brendan to our leadership team. His appointment comes at a time of significant opportunity and growth for CRISPR Therapeutics,” said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics. “Brendan’s business and financial expertise will be important in helping us continue to evolve the Company and realize our mission of transforming the lives of patients with serious diseases.” Dr. Kulkarni added: “On behalf of the Board of Directors, shareholders, and our employees, I want to thank Mike for his contributions as CFO and for his dedicated service since joining CRISPR Therapeutics. Mike has been a valuable part of the continued development of the Company, and we wish him all the best in his retirement and look forward to working with him on a smooth transition.” Prior to CRISPR Therapeutics, Mr. Smith was the Chief Financial Officer & Corporate Strategy of Translate Bio, a leading mRNA company that was recently acquired by Sanofi for $3.2B. Mr. Smith is an accomplished executive with more than two decades of experience within high-growth biopharma environments where he made significant contributions in various operations and strategy positions. In these positions, Mr. Smith provided strategic financial leadership relating to long-term growth planning focused on operational efficiencies, building manufacturing and supply capabilities, and evaluation of business development opportunities and commercial planning assessments. Previously, as a Partner at Boston Consulting Group, Mr. Smith led integrated biopharma client engagements that included planning and executing on R&D strategy, operations, business development and deal diligence. Prior to that, Mr. Smith was VP, Head of Business Operations for Worldwide R&D at Pfizer, where he led financial and headcount planning across discovery and development operations. Prior, in his role as Executive Director, Head of Business Strategy and Operations for Biologics Pharmaceutical Sciences at Pfizer, Mr. Smith led manufacturing and financial operations for the company’s global biologics process development organization. Mr. Smith received a B.S. in Biochemistry from Worcester Polytechnic Institute and an M.B.A. from Harvard Business School. About CRISPR Therapeutics CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com. CRISPR THERAPEUTICS® word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners. Investor Contact: Susan Kim +1-617-307-7503 susan.kim@crisprtx.com Media Contact: Rachel Eides +1-617-315-4493 rachel.eides@crisprtx.com
瑞士楚格和马萨诸塞州剑桥。2021年10月14日--专注于为严重疾病创造变革性基因药物的生物制药公司CRISPR治疗公司今天宣布任命布伦丹·史密斯为首席财务官,从今天起生效。史密斯先生拥有超过20年的财务、运营和战略领导经验,包括担任Translate Bio的首席财务官。他接替迈克尔·托姆西切克,后者在为公司服务四年后即将退休。预计Tomsicek先生将在2021年底前继续担任公司顾问,以帮助确保平稳过渡。 “我很高兴欢迎布兰登加入我们的领导团队。他的任命正值CRISPR治疗学迎来重大机遇和增长之际,“CRISPR治疗学首席执行官萨马特·库尔卡尼博士说。“布兰登的商业和财务专业知识将有助于我们继续发展公司,并实现我们改变严重疾病患者生活的使命。” 库尔卡尼博士补充说:“我代表董事会、股东和我们的员工,感谢迈克作为首席财务官所做的贡献,以及他自加入CRISPR治疗公司以来所做的奉献服务。迈克一直是公司持续发展的宝贵组成部分,我们祝愿他退休后一切顺利,并期待着与他合作平稳过渡。“ 在加入CRISPR治疗公司之前,史密斯先生是Translate Bio的首席财务官和企业战略。Translate Bio是一家领先的基因制药公司,最近被赛诺菲以3.2亿美元收购。史密斯先生是一位卓有成就的高管,在高增长的生物制药环境中拥有超过20年的经验,在各种运营和战略职位上做出了重要贡献。在这些职位上,史密斯先生提供了与长期增长规划有关的战略财务领导,重点是运营效率、建立制造和供应能力、评估业务发展机会和商业规划评估。此前,作为波士顿咨询集团的合伙人,史密斯先生领导了综合生物制药客户的工作,包括研发战略、运营、业务发展和交易调查的规划和执行。在此之前,史密斯先生是辉瑞全球研发业务运营副总裁,在那里他领导了发现和开发业务的财务和人员规划。在此之前,史密斯先生作为辉瑞生物制药科学的执行董事、商业战略和运营主管,领导了该公司全球生物工艺开发组织的制造和财务运营。史密斯先生获得了学士学位。伍斯特理工学院生物化学专业和工商管理硕士学位。哈佛商学院的。 关于CRISPR疗法 CRISPR/Caseutics是一家领先的基因编辑公司,专注于利用其专有的CRISPR/Cas9平台开发针对严重疾病的转化性基因药物。CRISPR/Cas9是一种革命性的基因编辑技术,允许对基因组DNA进行精确、定向的改变。CRISPR治疗学已经建立了一个治疗项目组合,涵盖了广泛的疾病领域,包括血红蛋白病、肿瘤学、再生医学和罕见疾病。为了加速和扩大其努力,CRISPR Therapeutics已与包括拜耳、Vertex Pharmaceuticals和ViaCyte,Inc.在内的领先公司建立了战略合作关系。CRISPR Therapeutics AG总部位于瑞士楚格,在美国拥有全资子公司CRISPR Therapeutics,Inc.以及位于马萨诸塞州剑桥的R&D业务,并在加利福尼亚州旧金山和英国伦敦设有业务办事处。欲了解更多信息,请访问www.crisprtx.com。 CRISPR Therapeutics®文字标记和设计标志是CRISPR Therapeutics AG的商标和注册商标。所有其他商标和注册商标都是其各自所有者的财产。 投资者联系方式: 苏珊·金 +1-617-307-7503 @crisprtx.com 媒体联系: 雷切尔·艾德斯 +1-617-315-4493 @crisprtx.com

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文